Durvalumab
Monoclonal antibody
Also known as MEDI4736
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Bladder Cancer, Biliary Tract Cancer, Small Cell Lung Cancer, Endometrial Cancer, Non-Muscle Invasive Bladder Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Ovarian Cancer · Phase 3Renal Cell Carcinoma · Phase 3Urothelial Carcinoma · Phase 3
Also approved (4)
- Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
- Non-Small Cell Lung Cancer (NSCLC)Imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements (for selection criteria, see section 5.1). Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum...
- Maintenance treatment of locally-advanced, unresectable non-small cell lung cancer following definitive chemoradiation therapy
- Locally Advanced or Metastatic Urothelial Carcinoma IMFINZI® (durvalumab for injection) is indicated for: • the treatment of patients with locally advanced or metastatic urothelial carcinoma who: - have disease progression during or following platinum-containing chemotherapy - have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Marketing authorization with conditions was based on a promising tumour response rate and durability of response. An improvement in survival or disease-related symptoms has not been established (see 14...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PACIFIC NCT02125461 · Non-Small Cell Lung Cancer Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251). Registry: NCT02125461 | 3 | Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.); Overall Survival (From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.) 2017-02-13 | Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) | Reliable signal | link ↗ |
View 4 more trials
ARCTIC NCT02352948 · Non - Small Cell Lung Cancer NSCLC This was a randomized, open-label, active-controlled phase 3 trial with hard clinical co-primary endpoints (overall survival and progression-free survival) in advanced NSCLC, but the key comparisons for durvalumab were not statistically significant: in sub-study B, durvalumab plus tremelimumab missed the OS and PFS superiority tests (OS HR 0.80, p=0.109; PFS HR 0.77, p=0.056), and in sub-study A, durvalumab monotherapy was underpowered with no formal statistical comparison performed. Because the primary endpoint was not met, the evidence is moderate rather than strong. Registry: NCT02352948 | 3 | Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months); Progression-Free Survival (PFS) (Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.) 2018-02-09 | Sub-study A: median OS 11.7 vs 6.8 months, HR 0.63 (95% CI 0.42-0.93); median PFS 3.8 vs 2.2 months, HR 0.71 (95% CI 0.49-1.04). Sub-study B: median OS 11.5 vs 8.7 months, HR 0.80 (95% CI 0.61-1.05; p=0.109); median PFS 3.5 vs 3.5 months, HR 0.77 (95% CI 0.59-1.01; p=0.056). | Partial signal | link ↗ |
PACIFIC2 NCT03519971 · Non-Small Cell Lung Cancer The study was randomized, double-blind, and placebo-controlled, with 219 participants receiving durvalumab and 109 receiving placebo alongside standard chemoradiation. Its primary clinical endpoint, progression-free survival, was not statistically significantly improved with durvalumab (13.8 vs 9.4 months; hazard ratio 0.85, p=0.247), so the results provide meaningful but inconclusive evidence of benefit. Registry: NCT03519971 | 3 | Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).) 2023-09-07 | Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) | Partial signal | link ↗ |
AEGEAN NCT03800134 · Non-Small Cell Lung Cancer This was a randomized, double-blind, placebo-controlled trial, and both primary endpoints were met: event-free survival (hazard ratio 0.68, p=0.004) and pathological complete response (17.2% vs 4.3%). The sources available for this trial do not report a sample-size (power) calculation, so it cannot be confirmed that the trial was adequately powered. Registry: NCT03800134 | 3 | Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population (Up to approximately 15 weeks after randomization); Event-Free Survival (EFS) in modified intent to treat (mITT) population (Up to 5.5 years after first patient randomized.) 2022-11-10 | Co-primary endpoints, perioperative durvalumab + neoadjuvant chemotherapy vs placebo + chemotherapy: event-free survival hazard ratio 0.68 (95% CI 0.53 to 0.88), p=0.004 at the first interim analysis; pathological complete response 17.2% vs 4.3%, difference 13.0 percentage points (95% CI 8.7 to 17.6), p<0.001 at interim (Heymach et al., N Engl J Med 2023). | Partial signal | link ↗ |
POSEIDON NCT03164616 · Non-Small Cell Lung Cancer This was a large randomized trial with a chemotherapy control arm, but it was open-label, so neither patients nor doctors were blinded. Progression was read by a blinded independent central review and survival is objective, so the open-label design does not bias these endpoints. Of its two primary endpoints, progression-free survival improved significantly (hazard ratio 0.74) while overall survival did not (hazard ratio 0.86, p=0.076), so the result is mixed. Registry: NCT03164616 | 3 | Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).); Overall Survival (OS); D + SoC Compared With SoC Alone (From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).) 2021-03-12 | Primary endpoints, durvalumab + chemotherapy vs chemotherapy alone: progression-free survival median 5.5 vs 4.8 months, hazard ratio 0.74 (95% CI 0.620 to 0.885), p=0.00093, met; overall survival median 13.3 vs 11.7 months, hazard ratio 0.86 (95% CI 0.724 to 1.016), p=0.07581, not significant (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (71)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (417)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (101)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (145)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (20)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (26)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other PD-L1 drugs
Atezolizumab, Avelumab, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), Adebrelimab, Envafolimab and 7 more. Compare all 13 PD-L1 drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Durvalumab: this drug | Approved | Monoclonal antibody | PD-L1 | Reliable signal | NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed | |
| Adagrasib (Krazati) | Approved | Small molecule | KRAS G12C | Partial signal | Featured results are non-efficacy only in this race | |
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | Partial signal | NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7) NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1) | |
| Alectinib (Alecensa) | Approved | Small molecule | ALK | Partial signal | NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6) | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | Partial signal | NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results. NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44) | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | Partial signal | NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1) | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | Partial signal | NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | Partial signal | NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006). | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | Reliable signal | NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). | |
| Binimetinib | Approved | Small molecule | MEK1/2 | Weak signal | No reviewed efficacy summary in this indication | |
| Brigatinib | Approved | Small molecule | ALK | Partial signal | NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01) | |
| Capmatinib | Approved | Small molecule | MET | Weak signal | NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1). | |
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7) | |
| Ceritinib | Approved | Small molecule | ALK | Partial signal | NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8) | |
| Crizotinib | Approved | Small molecule | ALK, ROS1, MET/HGFR, and RON | Partial signal | NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7) NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2) | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | Weak signal | NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%). NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20 | |
| Dacomitinib PF-00299804 | ApprovedUS marketing discontinued | Small molecule | EGFR/HER1, HER2, HER4 | Partial signal | NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11) NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed | |
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | Partial signal | NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | Weak signal | NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8) | |
| Ensartinib (Ensacove) | Approved | Small molecule | ALK | Partial signal | NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. | |
| Entrectinib | Approved | Small molecule | ROS1/NTRK | not yet graded | No reviewed efficacy summary in this indication | |
| Erlotinib | Approved | Small molecule | EGFR | Partial signal | NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results). | |
| Gefitinib | Approved | Small molecule | EGFR | Partial signal | NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | Partial signal | NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | Partial signal | NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Larotrectinib | Approved | Small molecule | TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions) | not yet graded | No reviewed efficacy summary in this indication | |
| Lazertinib | Approved | Small molecule | EGFR | Partial signal | NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44) | |
| Lorlatinib | Approved | Small molecule | ALK / ROS1 | Partial signal | No reviewed efficacy summary in this indication | |
| Nab-Paclitaxel | Approved | Small molecule | Microtubules | Partial signal | NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5) | |
| Necitumumab | Approved | Monoclonal antibody | Epidermal growth factor receptor (EGFR) | Partial signal | NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1) NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Osimertinib (Tagrisso) | Approved | Small molecule | EGFR | Partial signal | NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | Partial signal | Featured results are non-efficacy only in this race | |
| Pemetrexed (Alimta) | Approved | Small molecule | Thymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFT | Partial signal | NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12) NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83) | |
| Porfimer Sodium | Approved | Small molecule | Photoactivated radicals | Weak signal | Featured results are safety and non-efficacy only in this race | |
| Pralsetinib | Approved | Small molecule | RET | Partial signal | NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5) NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106). | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL). | |
| Repotrectinib | Approved | Small molecule | ROS1/NTRK | not yet graded | No reviewed efficacy summary in this indication | |
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj) | Approved | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Selpercatinib (Retevmo) | Approved | Small molecule | RET | Partial signal | NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026) NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002 | |
| Sevabertinib (Hyrnuo) | Approved | Small molecule | EGFR/HER2 | Weak signal | No reviewed efficacy summary in this indication | |
| Sotorasib | Approved | Small molecule | KRAS G12C | Partial signal | NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68) NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more. | |
| Sunvozertinib (Zegfrovy) | Approved | Small molecule | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Taletrectinib | Approved | Small molecule | ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | Partial signal | No reviewed efficacy summary in this indication | |
| Telisotuzumab Vedotin | Approved | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Tepotinib (Tepmetko) | Approved | Small molecule | MET | Weak signal | NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months | |
| Trametinib | Approved | Small molecule | MEK1/2 | Partial signal | NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20 | |
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | Weak signal | NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70) | |
| Tremelimumab | Approved | Monoclonal antibody | CTLA-4 | Partial signal | NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| Zidesamtinib | Approved | Small molecule | ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | Reliable signal | NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) | |
| Zongertinib (Hernexeos) | Approved | Small molecule | HER2 Mutant-selective | not yet graded | No reviewed efficacy summary in this indication | |
| 7MW3711 | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Aglatimagene Besadenovec | Phase 3 | Gene therapy / editing | Herpes simplex virus thymidine kinase (HSV-tk) gene product | not yet graded | No reviewed efficacy summary in this indication | |
| Apatinib | Phase 3 | Small molecule | VEGFR2 | Partial signal | NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%. | |
| APG-2449 | Phase 3 | Small molecule | FAK / ALK / ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Phase 3 | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | Weak signal | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | Partial signal | NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. | |
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | Partial signal | NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed | |
| Envafolimab | Phase 3 | Monoclonal antibody | PD-L1 | Weak signal | NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months | |
| Fetrastobart Vedotin | Phase 3 | Antibody–drug conjugate | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | Reliable signal | NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001 | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Phase 3 | Small molecule | PARP1/2 | Partial signal | NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Phase 3 | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Obrixtamig | Phase 3(overall) | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 | Reliable signal | NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Pumitamig | Phase 3 | Multispecific antibody | PD-L1 and VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Risvutatug Rezetecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Govitecan | Phase 3 | Antibody–drug conjugate | TROP2 | Partial signal | NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | Partial signal | NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 | |
| Savolitinib (Orpathys) | Phase 3 | Small molecule | MET | Partial signal | NCT05261399: SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. NCT05015608: Median PFS (SACHI trial, ITT): 8.2 months savolitinib+osimertinib vs 4.5 months chemotherapy; in patients prior on 1st/2nd-gen EGFR-TKI: 9.8 vs 5.4 months; predefined significance thresholds met in both populations | |
| Serplulimab | Phase 3 | Monoclonal antibody | PD-1 | Weak signal | NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67). NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628). | |
| Sotiburafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 / VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Sugemalimab (Cejemly) | Phase 3 | Monoclonal antibody | PD-L1 | Reliable signal | NCT03728556: Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84 NCT03789604: Sugemalimab plus chemotherapy improved investigator-assessed PFS at interim analysis: median 7.8 vs 4.9 months, stratified HR 0.50. | |
| Tislelizumab | Phase 3 | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Budigalimab | Phase 2/3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| HLX43 | Phase 2/3 | Antibody–drug conjugate | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| AL8326 | Phase 2 | Small molecule | Aurora B / FGFR / VEGFR (multi-kinase) | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 2 | Antibody–drug conjugate | HER2 | Weak signal | No reviewed efficacy summary in this indication | |
| Erdafitinib (Balversa) | Phase 2 | Small molecule | FGFR1-4 | Weak signal | NCT02699606: NSCLC cohort (n=12): objective response rate 0% (no CR or PR); disease control rate 25.0% (95% CI 5.5-57.2%); 3 patients stable disease, 2 with tumor shrinkage >20%. missed | |
| Ifinatamab Deruxtecan | Phase 2 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| JS207 | Phase 2 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 2 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Olvimulogene Nanivacirepvec | Phase 2 | Oncolytic virus | No discrete molecular target | not yet graded | No reviewed efficacy summary in this indication | |
| Raludotatug Deruxtecan | Phase 2 | Antibody–drug conjugate | CDH6 (Cadherin-6) | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 2 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Tagitanlimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| TUB-040 | Phase 2 | Antibody–drug conjugate | NaPi2b (sodium-dependent phosphate transporter, SLC34A2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ubamatamab | Phase 2 | Monoclonal antibody | MUC16 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Phase 2 | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 2 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-B2033 | Phase 1/2 | Multispecific antibody | GPC3 (glypican-3) x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| Cetrelimab | Phase 1/2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Phase 1/2 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Nilvanstomig | Phase 1/2 | Biologic (subtype unspecified) | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Puxitatug Samrotecan | Phase 1/2 | Antibody–drug conjugate | B7-H4 | not yet graded | No reviewed efficacy summary in this indication | |
| Quaratusugene Ozeplasmid (Reqorsa) | Phase 1/2 | Gene therapy / editing | TUSC2 (tumor suppressor gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Rezatapopt | Phase 1/2 | Small molecule | p53 reactivator | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 1/2 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tuvutromstat | Phase 1/2 | Small molecule | MAT2A | Weak signal | No reviewed efficacy summary in this indication | |
| 177Lu-RAD204 | Phase 1 | Radiopharmaceutical | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-324 | Phase 1 | Antibody–drug conjugate | Glypican-3 (GPC3) / Topoisomerase I | not yet graded | No reviewed efficacy summary in this indication | |
| AKY-1189 | Phase 1 | Radiopharmaceutical | Nectin-4 (PVRL4) | not yet graded | No reviewed efficacy summary in this indication | |
| BPI-371153 | Phase 1 | Small molecule | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| IBC-Ab002 | Phase 1(overall) | Monoclonal antibody | PD-L1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ixotatug Vedotin | Phase 1 | Antibody–drug conjugate | Claudin 6 (CLDN6) | not yet graded | No reviewed efficacy summary in this indication | |
| LY4052031 | Phase 1 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Sofetabart Mipitecan | Phase 1 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 126 furthest-along competitors are listed; 485 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(204 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Durvalumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (32)
November 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2026 (26)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (81)
January 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (4)
What to watch
What to watch
What to watch
What to watch
March 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (4)
What to watch
What to watch
What to watch
What to watch
September 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (1)
What to watch
December 2027 (16)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (43)
January 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (3)
What to watch
What to watch
What to watch
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (2)
May 2028 (2)
June 2028 (2)
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (4)
What to watch
What to watch
What to watch
November 2028 (4)
What to watch
What to watch
What to watch
What to watch
December 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (24)
January 2029 (2)
February 2029 (3)
What to watch
What to watch
What to watch
March 2029 (1)
What to watch
April 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (4)
What to watch
What to watch
What to watch
What to watch
August 2029 (3)
What to watch
What to watch
What to watch
September 2029 (3)
What to watch
What to watch
What to watch
October 2029 (3)
What to watch
What to watch
What to watch
November 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (16)
January 2030 (3)
What to watch
What to watch
What to watch
February 2030 (1)
What to watch
March 2030 (1)
What to watch
April 2030 (3)
What to watch
What to watch
May 2030 (4)
What to watch
What to watch
What to watch
What to watch
June 2030 (1)
What to watch
August 2030 (1)
What to watch
December 2030 (2)
What to watch
What to watch
2031 (3)
June 2031 (1)
What to watch
November 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (3)
May 2032 (1)
What to watch
July 2032 (1)
What to watch
August 2032 (1)
What to watch
2033 (1)
January 2033 (1)
What to watch
2039 (1)
July 2039 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent